Essential Pharma, an international speciality pharma group, has been granted new establishment and licences in Switzerland and Malta.
Firstly, following a successful inspection by Swissmedic, Essential Pharma has been granted an establishment licence in Switzerland, which will allow the company to significantly enhance its supply chain efficiency for a wide range of important medicinal products.
This represents a significant broadening of the company's operating platform when combined with its existing Good Distribution Practice (GDP) operations in the UK and EU. It will apply to transactions for both finished and unfinished pharmaceuticals, allowing importing, exporting, wholesaling and trading abroad.
Secondly, the company has been granted a Manufacturing & Importation Authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection by the Malta Medicines Authority.
The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater flexibility in how the business manages the flow of medicines across its territories.
Steen Vansgaard, Chief Executive Officer of Essential Pharma, commented: "These two most recent licence approvals for Essential Pharma will allow us to support a broader range of essential medicines and improve our supply for patients across international markets."
Vansgaard added: "The successful advancement of our operating infrastructure, following our acquisition by Gyrus, is a key step designed to support the company's ambitious organic and inorganic growth plans as we seek new opportunities to diversify our portfolio and build our competitive market presence. We believe that this rapid progress in extending and strengthening our operating platform will enhance our appeal as a trusted partner to multiple pharma companies of all sizes looking to streamline their portfolios."